Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REPLICA: Real Patient Life Treatment With Cabozantinib in Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic RCC: a Descriptive and Prospective Non Interventional Study.

NCT04106349 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT04106349
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04106349 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REPLICA: Real Patient Life Treatment With Cabozantinib in Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic RCC: a Descriptive and Prospective Non Interventional Study.
Lead sponsor
Ipsen
Phase
Observational
Overall status
Active, not recruiting
Start date
March 3, 2020
Completion date
March 31, 2027
Enrollment
150 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic renal cell carcinoma